Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 354-360

  Sheu, Tiffany G ^a   Deyde, Varough M ^a   Garten, Rebecca J ^a   Klimov, Alexander I ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Evolution; Genetic analysis; Influenza B; Neuraminidase; Resistance

Indexed keywords

ARGININE; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; MOLECULAR MARKER; OSELTAMIVIR; SERINE; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; GENETIC MARKER; GENOME ANALYSIS; INFLUENZA VIRUS B; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PYROSEQUENCING; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA PRIMERS; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; INFLUENZA B VIRUS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; POLYMORPHISM, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VICTORIA; VIRAL PROTEINS; ZANAMIVIR;

INFLUENZA B VIRUS; ORTHOMYXOVIRIDAE;

EID: 74449091893     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.022     Document Type: Article

References (36)

1. Baum E.Z., Wagaman P.C., Ly L., Turchi I., Le J., Bucher D., and Bush K. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res. 59 1 (2003) 13-22
2. Besselaar T.G., Naidoo D., Buys A., Gregory V., and McAnerney J. Widespread oseltamivir resistance in influenza A virus (H1N1), South Africa. Emerg. Infect. Dis. 14 11 (2009) 1809-1810
3. Boivin G., Goyette N., and Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 34 5 (2002) E23-E25
4. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 9492 (2005) 1175-1181
5. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 8 (2006) 891-894
6. Colman P.M. Neuraminidase: enzyme and antigen. In: Krug R.M. (Ed). The Influenza Viruses vol. 4 (1989), Plenum Press, New York 175-210
7. Deyde V.M., Nguyen T., Bright R.A., Balish A., Shu B., Lindstrom S., Klimov A.I., and Gubareva L.V. Detection of molecular markers of antiviral resistance in influenza A(H5N1) viruses using a pyrosequencing method. Antimicrob. Agents Chemother. 53 3 (2009) 1039-1047
8. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., Klimov A.I., and Gubareva L.V. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81 1 (2009) 16-24
9. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., and Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 2 (2007) 249-257
10. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epeprson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M., and Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 10 (2009) 1034-1041
11. Duwe S., and Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153 2 (2008) 134-141
12. Ferraris O., and Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41 1 (2008) 13-19
13. Gubareva L., Okomo-Adhiambo M., Deyde V., Fry A.M., Sheu T.G., Garten R., Smith C., Barnes J., Myrick A., Shaw M., Bridges C., Klimov A., and Cox N. Update: drug susceptibility of swine-origin influenza A(H1N1) viruses, April 2009. Morb. Mortal. Wkly. Rep. 58 16 (2009) 433-435
14. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 5 (1998) 1257-1262
15. Hatakeyama S., Sugaya N., Ito M., Yamazaki M., Ichikawa M., Kimura K., Kiso M., Shimizu H., Kawakami C., Koike K., Mitamura K., and Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297 13 (2007) 1435-1442
16. Hauge S.H., Blix H.S., Borgen K., Hungnes O., Dudman S.G., and Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol. J. 6 (2009) 54
17. Hay A.J., Zambon M.C., Wolstenholme A.J., Skehel J.J., and Smith M.H. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18, Suppl. B: (1986) 19-29
18. Hayden F.G. Amantadine and rimantadine-clinical aspects. In: Richman D.D. (Ed). Antiviral Drug Resistance vol. 4 (1996), John Wiley & Sons Ltd. 59-77
19. Higgins R.R., Eshaghi A., Burton L., Mazzulli T., and Drews S.J. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada. J. Clin. Virol. 44 1 (2009) 91-93
20. Hurt A.C., Barr I.G., Hartel G., and Hampson A.W. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62 1 (2004) 37-45
21. Hurt A.C., Iannello P., Jachno K., Komadina N., Hampson A.W., Barr I.G., and McKimm-Breschkin J.L. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 50 5 (2006) 1872-1874
22. Ison M.G., Gubareva L.V., Atmar R.L., Treanor J., and Hayden F.G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193 6 (2006) 760-764
23. Kawai N., Ikematsu H., Iwaki N., Kawashima T., Maeda T., Mitsuoka S., Kondou K., Satoh I., Miyachi K., Yamaga S., Shigematsu T., Hirotsu N., and Kashiwagi S. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J. Infect. 55 3 (2007) 267-272
24. Klimov A.I., Rocha E., Hayden F.G., Shult P.A., Roumillat L.F., and Cox N.J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 172 5 (1995) 1352-1355
25. Lackenby A., Democratis J., Siqueira M.M., and Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 13 6 (2008) 809-820
26. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., and Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13 5 (2008)
27. McCullers J.A., Wang G.C., He S., and Webster R.G. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J. Virol. 73 9 (1999) 7343-7348
28. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 7 (2003) 2264-2272
29. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 7 (2006) 2395-2402
30. Mungall B.A., Xu X., and Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 103 1-2 (2004) 195-197
31. Nerome R., Hiromoto Y., Sugita S., Tanabe N., Ishida M., Matsumoto M., Lindstrom S.E., Takahashi T., and Nerome K. Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Arch. Virol. 143 8 (1998) 1569-1583
32. Rota P.A., Hemphill M.L., Whistler T., Regnery H.L., and Kendal A.P. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J. Gen. Virol. 73 Part 10 (1992) 2737-2742
33. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., and Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52 9 (2008) 3284-3292
34. Xu X., Lindstrom S.E., Shaw M.W., Smith C.B., Hall H.E., Mungall B.A., Subbarao K., Cox N.J., and Klimov A. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 103 1-2 (2004) 55-60
35. Zou S., Prud'homme I., and Weber J.M. Evolution of the hemagglutinin gene of influenza B virus was driven by both positive and negative selection pressures. Virus Genes 14 3 (1997) 181-185
36. Zwickl, D.J. 2006. Genetic Algorithm Approaches for the Phylogenetic Analysis of Large Biological Sequence Datasets Under the Maximum Likelihood Criterion. PhD dissertation. The University of Texas at Austin.